Scarica l'app Stockscreener
1.96
0.51%
0.01
Dopo l'orario di chiusura:
1.95
-0.01
-0.51%
Sangamo Therapeutics Inc Borsa (SGMO) Ultime notizie
Analysts Just Made A Massive Upgrade To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Forecasts - Simply Wall St
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain - BioSpace
Sangamo stock climbs 12% post-market on FDA update for ST-503 - MSN
Sangamo Therapeutics Gets FDA Clearance for Investigational NDA for Pain Treatment - Marketscreener.com
Sangamo's Novel Gene Therapy for Chronic Pain Gets FDA Clearance for Clinical Trials | SGMO Stock News - StockTitan
What is HC Wainwright's Forecast for SGMO FY2024 Earnings? - MarketBeat
FY2028 Earnings Forecast for SGMO Issued By HC Wainwright - MarketBeat
Sangamo Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Sangamo Therapeutics (NASDAQ:SGMO) Price Target Raised to $9.00 at Barclays - MarketBeat
Sangamo Therapeutics' SWOT analysis: gene therapy firm's stock faces challenges, opportunities - Investing.com Canada
Sangamo: Q3 Earnings Snapshot - Marketscreener.com
Sangamo Therapeutics (SGMO) Tops Q3 Earnings and Revenue Estimates - MSN
Earnings call: Sangamo Therapeutics reports progress in gene therapies By Investing.com - Investing.com Australia
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Sangamo Therapeutics reports progress in gene therapies - Investing.com India
Sangamo Therapeutics Inc (SGMO) Q3 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
SGMOSangamo Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Sangamo Therapeutics Inc (SGMO) Q3 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Sangamo Therapeutics Q3 beats propel stock 5% higher - MSN
Sangamo Therapeutics earnings beat by $0.06, revenue topped estimates - Investing.com UK
Sangamo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results - Business Wire
Sangamo Therapeutics's Earnings Outlook - Benzinga
FY2024 Earnings Forecast for SGMO Issued By HC Wainwright - Defense World
Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market EvolutionTechnavio - The Malaysian Reserve
Equities Analysts Set Expectations for SGMO FY2024 Earnings - MarketBeat
Sangamo Therapeutics (NASDAQ:SGMO) Reaches New 12-Month High on Analyst Upgrade - Defense World
Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences - The Manila Times
Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences - GlobeNewswire Inc.
Sangamo (SGMO) Stock Rally Continues In Pre-Market Ahead of Financial Results Release - Stocks Telegraph
Sangamo Therapeutics (SGMO) Set to Announce Quarterly Earnings on Tuesday - MarketBeat
Sangamo Therapeutics (NASDAQ:SGMO) Price Target Raised to $10.00 at HC Wainwright - MarketBeat
Vanguard Group Inc's Strategic Reduction in Sangamo Therapeutics Inc - GuruFocus.com
Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast - StockTitan
individual investors who own 55% along with institutions invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) saw increase in their holdings value last week - Yahoo Finance
Sangamo Therapeutics (NASDAQ:SGMO) Stock Crosses Above 200 Day Moving Average – Here’s Why - Defense World
Sangamo Therapeutics (NASDAQ:SGMO) Stock Passes Above 200 Day Moving AverageWhat's Next? - MarketBeat
Gene Therapy Market Detailed Analysis and Forecast to 2031 - InsightAce Analytic
StockWatch: Sangamo Shares Surge on Shorter Pathway for Fabry Candidate - Genetic Engineering & Biotechnology News
Fabry disease gene therapy study data enough for FDA submission - Fabry Disease News
Prime Medicine Spat with Tessera Rumbles on at ESGCT - Genetic Engineering & Biotechnology News
Booz Allen Posts Upbeat Q3 Earnings, Joins Deckers Outdoor, Saia, Boyd Gaming And Other Big Stocks Moving Higher On FridayBooz Allen Hamilton (NYSE:BAH) - Benzinga
Sangamo Therapeutics' SWOT analysis: genomic medicine stock at crossroads - Investing.com
Sangamo Therapeutics' SWOT analysis: genomic medicine stock at crossroads By Investing.com - Investing.com UK
4 Analysts Have This To Say About Sangamo Therapeutics - Benzinga
What Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 26% Share Price Gain Is Not Telling You - Simply Wall St
Sangamo shares jump as FDA clears faster gene therapy pathway - The Pharma Letter
Sangamo stock rallies 37% on FDA update for Fabry disease drug - MSN
Sangamo Therapeutics, Cyclacel Pharma, GE Aerospace: 3 Stocks Retailers Are Most Bullish Tuesday Afternoon - Barchart
Sangamo Therapeutics (NASDAQ:SGMO) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
Traders Purchase Large Volume of Call Options on Sangamo Therapeutics (NASDAQ:SGMO) - MarketBeat
0.93%
3.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):